Abbott Laboratories $ABT Shares Sold by Gradient Investments LLC

Posted by Stanley Muller on Oct 8th, 2026

Gradient Investments LLC lowered its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 24.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 178,998 shares of the healthcare product maker’s stock after selling 57,265 shares during the period. Gradient Investments LLC’s holdings in Abbott Laboratories were worth $17,690,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in ABT. BlackRock Inc. grew its holdings in Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after acquiring an additional 6,769,518 shares in the last quarter. State Street Corp increased its holdings in Abbott Laboratories by 1.7% in the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock valued at $7,343,246,000 after buying an additional 1,350,766 shares during the last quarter. J. Stern & Co. LLP raised its stake in Abbott Laboratories by 12,439.6% during the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after buying an additional 39,005,451 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in Abbott Laboratories by 0.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,887,109 shares of the healthcare product maker’s stock worth $2,241,076,000 after buying an additional 118,014 shares during the last quarter. Finally, Bank of America Corp DE acquired a new position in shares of Abbott Laboratories in the 2nd quarter worth approximately $1,603,607,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective on the stock in a research note on Thursday, August 13th. Piper Sandler restated an “overweight” rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Wells Fargo & Company boosted their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. BTIG Research raised their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Finally, Barclays assumed coverage on Abbott Laboratories in a report on Wednesday. They set an “overweight” rating and a $120.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average price target of $118.88.

Read Our Latest Stock Report on ABT

Abbott Laboratories Price Performance

Shares of NYSE:ABT traded down $0.45 during trading on Thursday, reaching $98.28. The company had a trading volume of 3,090,664 shares, compared to its average volume of 11,302,686. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $135.13. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The firm has a market capitalization of $170.06 billion, a PE ratio of 31.85, a price-to-earnings-growth ratio of 1.82 and a beta of 0.59. The firm’s fifty day moving average is $106.52 and its 200 day moving average is $98.39.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period last year, the company posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.6%. Abbott Laboratories’s payout ratio is currently 81.55%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Barclays initiated coverage of Abbott Laboratories with an Overweight rating and a $120 price target, implying approximately 23% upside from the recently quoted share price. The bullish view supports ABT by pointing to potential value at current levels. Abbott Laboratories Now Covered by Analysts at Barclays
Positive Sentiment: Barclays also listed Abbott among its overweight medtech ideas as it turned more constructive on the sector. Additional positive analyst sentiment could help offset recent selling pressure. Stryker, Abbott among overweight ideas as Barclays turns bullish on MedTech
Positive Sentiment: The FDA approved updates to Abbott’s CardioMEMS heart-failure system, adding smartphone-based pulmonary-pressure readings and clinician-guided treatment adjustments. The CardioGuide HF App and Dynamic Treatment Plan strengthen Abbott’s connected cardiac-care offering and could support future adoption. FDA-Approved CardioMEMS App Integration
Positive Sentiment: Abbott partnered exclusively with Berry Street to connect its over-the-counter Lingo glucose biosensor with insurance-supported nutrition coaching. The arrangement expands potential use cases for Abbott’s diabetes and metabolic-health technology. Abbott Ties Glucose Tracking to Live Nutrition Coaching
Neutral Sentiment: Abbott introduced Ensure Max Protein 3-in-1 Muscle Support, combining protein, creatine, and HMB in one serving. The launch broadens Abbott’s consumer-health portfolio, although its near-term financial impact is unclear. Abbott Introduces Ensure Max Protein 3-in-1 Muscle Support
Neutral Sentiment: Investor interest in ABT remains elevated, while its record of 411 consecutive quarterly dividend payments continues to appeal to income-focused investors. These factors may provide support but do not directly change earnings expectations. Is Abbott Laboratories a Dividend Bargain After Its 2026 Selloff?
Negative Sentiment: Despite the bullish analyst commentary, ABT has remained under pressure after a difficult 2026 performance. Commentary that Abbott is not showing rapid growth, combined with a relatively elevated earnings multiple, may be limiting investor enthusiasm. Abbott Stock Drops Despite Market Gains

About Abbott Laboratories

(Free Report)

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.